Connecticut

Overview

Connecticut legalized medical cannabis in June 2012 under Governor Dannel Malloy. Adult-use cannabis was legalized on June 22, 2021 when Governor Ned Lamont signed Senate Bill 1201 (the Responsible and Equitable Regulation of Adult-Use Cannabis Act, or RERACA) effective July 1, 2021. Home cultivation for adults became effective July 1, 2023.

Both programs are regulated by the Connecticut Department of Consumer Protection (DCP).

Adult-use (RERACA, 2021)

• Public possession: 1.5 ounces.
• In-residence or locked vehicle trunk/glove box: up to 5 ounces.
• Home cultivation: up to 6 plants per household (3 mature, 3 immature), indoors only. Outdoor cultivation remains prohibited.
• Unlicensed gifting: permitted with no compensation; sale without license remains criminal.
• Delta-8 / Delta-9 / Delta-10 THC: classified as cannabis and subject to the same regulatory framework.
• Past convictions: thousands of low-level cannabis convictions automatically expunged effective January 1, 2023.

Medical program (2012)

Codified at Conn. Gen. Stat. § 21a-408 et seq. The DCP maintains the Medical Marijuana Program registry.

Qualifying conditions

The Connecticut DCP enumerates a substantial qualifying-condition list, including:

• Cancer, ALS, HIV/AIDS, MS, Parkinson's, epilepsy, Crohn's, IBD
• Glaucoma, sickle-cell disease, severe psoriasis, severe rheumatoid arthritis
• Chronic pain associated with a medical condition
• Post-traumatic stress disorder
• Terminal illness

Patient access

• Possession: up to 5 ounces at home; monthly allocation set by the certifying practitioner.
• Approved forms: flower, edibles, oils, tinctures, capsules, vapes, topicals.
• Home cultivation: patients may use the adult-use 6-plant household rights.
• Reciprocity: Connecticut does not formally recognize out-of-state medical cards; visiting patients aged 21+ may purchase from any adult-use retailer.

Patients and caregivers

• Patient minimum age: 18. Minor patients require a designated caregiver and practitioner certification.
• Caregiver minimum age: 18 (Connecticut is among the states permitting younger caregivers; verify against current DCP rule).
• Caregivers per patient: up to 1 designated caregiver per patient.
• Caregiver registration: via DCP; criminal background check.

Patient registration steps

1. Schedule a visit with a Connecticut-licensed physician, APRN, or PA willing to certify cannabis use. The certifying provider must establish a bona fide patient-provider relationship.
2. The provider submits the written certification through the DCP Medical Marijuana Program online registry.
3. The patient completes the application through the DCP portal, submits identity documents, proof of Connecticut residency, and a current photo. The standard registration fee is $100; reduced to $25 for patients receiving Medicaid, Medicare, or SSDI.
4. Approved patients receive a state-issued registry ID card. The card authorizes purchases at any licensed Connecticut medical dispensary under medical-program pricing and the practitioner's monthly allocation.

Minor patients require a designated caregiver and additional documentation. The caregiver completes a separate application and Connecticut State Police background check.

Reciprocity and visiting patients

Connecticut's framework is dual-track for visitors:

• Adult-use: any visitor 21 or older with a government-issued photo ID may purchase from a licensed adult-use retailer under the 1.5 oz public possession cap.
• Medical: Connecticut does not formally recognize out-of-state medical cards. Visiting medical patients access cannabis through the adult-use retail framework if 21 or older.

The dual-track framework provides functional access to most adult visitors but no separate medical-program reciprocity. Visiting medical patients cannot access medical-only products, tax exemptions, or supply allocations available to in-state patients.

Employment and workplace

Connecticut provides significant employment protection for both medical patients and adult-use consumers under RERACA and follow-on legislation. Key provisions:

• Pre-employment testing: RERACA prohibits adverse hiring action based solely on a positive pre-employment THC test for most positions, with carve-outs for safety-sensitive roles, federal-contractor positions, and certain regulated industries.
• Off-duty use: employees retain protection for off-duty cannabis use that does not produce on-the-job impairment, subject to safety-sensitive and federal-contractor carve-outs.
• Federal contractor and DOT-regulated positions: federal drug-free workplace and DOT testing rules supersede state-level protection.
• Workers' compensation: post-incident testing positive for THC may still result in benefit denial if impairment at the time of incident is established.
• Medical patient protection: the medical-cannabis statute layers additional patient-status protection on top of the RERACA framework.

Connecticut's employment-protection framework is among the more patient-favorable in the United States, although the safety-sensitive carve-out remains broad and litigation continues to define its boundaries.

Hemp-derived intoxicants

Connecticut closed the hemp-derived intoxicating cannabinoid loophole through legislation that classifies delta-8 THC, delta-9 THC, delta-10 THC, and similar compounds as cannabis subject to the same regulatory framework regardless of plant source. The result: hemp-derived intoxicating products cannot be sold outside the licensed adult-use or medical-cannabis supply chain. Enforcement is by the DCP Bureau of Cannabis Compliance.

Recent legislative history

Notable post-2021 developments:

• 2021: RERACA enacted.
• 2022: PA 22-103 (the "Trailer Bill") refined social-equity provisions, license application rules, and packaging requirements.
• 2023: licensed adult-use retail sales began January 10; home cultivation became effective July 1; mass expungement of prior cannabis convictions took effect January 1.
• 2024: PA 24-76 adjusted on-premises consumption pilot framework and refined social-equity license categories.
• 2025-2026: continued legislative work on advertising, packaging, banking access, and tax-rate adjustments.

The April 2026 federal Schedule III rescheduling order produced no immediate Connecticut legislative response. DCP issued operator guidance confirming that state-level licensing and compliance obligations are unchanged.

Social equity and expungement

RERACA established a substantive social-equity framework prioritizing license applications from individuals from disproportionately impacted areas (defined by historical cannabis conviction rate and median household income). The framework also authorized the automatic expungement of thousands of low-level cannabis convictions effective January 1, 2023, executed through the Connecticut Judicial Branch with no application required from the affected individuals.

Federal context

Federal jurisdiction layers additional exposure on federal land, federal courthouses, military installations (Naval Submarine Base New London, Naval Submarine School), and interstate highways. I-91, I-84, I-95, and I-395 corridors see federal drug-interdiction activity, particularly at the New York, Massachusetts, and Rhode Island borders (all four states have legal adult-use cannabis, reducing cross-state purchase pressure).